Indeed, up to now, syntenin was unambiguously considered a valuable target for cancer therapy, and several inhibitors have already been developed and tested in preclinical models (Kegelman et al, 2017; Leblanc et al, 2020; Pradhan et al, 2020, 2021). Here, SDCBP is linked to cancer.